冠状动脉支架术后应用氯吡格雷及阿司匹林联合抗血小板治疗再狭窄率仍然很高。人体内药物转运体、代谢酶，及作用靶点的基因多态性目前发现对药物的血药浓度及治疗效果有影响但还没有明确的结论。本研究对支架术后联合抗血小板治疗人群进行药物代谢及药物作用位点相关遗传因素与临床结局的相关性进行前瞻性随访研究，以治疗的最终结局为核心，以临床、分子流行病学研究方法为工具，随访结束时以冠状动脉造影为金标准分为再狭窄和无再狭窄队列，比较两个队列的血小板聚集率、血药浓度、以及药物转运、代谢、药物作用受体相关的SNPs，在以上各层面评估其对临床结局的影响，分析药物抵抗的机制。从而得出对临床结局有预示意义的血小板聚集率水平、血药浓度水平及有意义的SNPs。为个体化治疗的必要性提供科学依据。

Clopidogrel and aspirin combination antiplatelet therapy restenosis rate is still high after Percutaneous Coronary Intervention with stent. Gene polymorphism of Drug transporter, metabolic enzymes and target sites of these drugs effected the blood concentrations of drugs and treatment outcome, But still have no definite conclusion. This study is prospective follow-up study about the effect of Genetic factors of drug transport, metabolism and target sites on treatment outcome of antiplatelet therapy after Percutaneous Coronary Intervention (PCI) with stent. the clinical and molecular epidemiology methods were used at the same time. These PCI patient are divided into restenosis and no restenosis queue by coronary angiography at the end of the follow-up. The blood drug concentration, platelet aggregation rate and gene polymorphism of the drug transport, metabolism Enzyme, drug target site are analyzed between the two group and their influence on clinical outcome are also assessed. Then we can get platelet aggregation rate, blood drug concentration and meaningful SNPs which can predict clinical outcome significantly and to provide scientific basis for the necessity of individualized treatment.